Monitoring gastric cancer progression with circulating tumour DNA.
Br J Cancer
; 112(2): 352-6, 2015 Jan 20.
Article
en En
| MEDLINE
| ID: mdl-25490524
ABSTRACT
BACKGROUND:
Circulating tumour DNA (ctDNA) is an emerging candidate biomarker for malignancies and may be useful for monitoring the disease status of gastric cancer.METHODS:
We performed targeted deep sequencing of plasma cell-free DNA (cfDNA) by massively parallel sequencing in patients with tumours harbouring TP53 mutations. The quantitative values of TP53-ctDNA during the clinical course were compared with the tumour status.RESULTS:
Three out of ten patients with TP53 mutations in primary tumours showed detectable TP53 mutation levels in preoperative cfDNA. Although the cfDNA concentrations were not always reflective of the disease course, the ctDNA fraction correlated with the disease status.CONCLUSIONS:
ctDNA may serve as a useful biomarker to monitor gastric cancer progression and residual disease.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias Gástricas
/
ADN de Neoplasias
/
Biomarcadores de Tumor
Tipo de estudio:
Observational_studies
Límite:
Aged
/
Aged80
/
Humans
/
Male
Idioma:
En
Revista:
Br J Cancer
Año:
2015
Tipo del documento:
Article
País de afiliación:
Japón